SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Saved in:
| Title: | SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. |
|---|---|
| Authors: | van Hazel GA; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France. gvh@perthoncology.com.au., Heinemann V; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Sharma NK; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Findlay MP; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Ricke J; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Peeters M; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Perez D; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Robinson BA; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Strickland AH; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Ferguson T; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Rodríguez J; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Kröning H; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Wolf I; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Ganju V; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Walpole E; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Boucher E; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Tichler T; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Shacham-Shmueli E; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Powell A; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Eliadis P; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Isaacs R; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Price D; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Moeslein F; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Taieb J; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Bower G; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Gebski V; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Van Buskirk M; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Cade DN; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Thurston K; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France., Gibbs P; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 May 20; Vol. 34 (15), pp. 1723-31. Date of Electronic Publication: 2016 Feb 22. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 26903575 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22van+Hazel+GA%22">van Hazel GA</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France. gvh@perthoncology.com.au.<br /><searchLink fieldCode="AU" term="%22Heinemann+V%22">Heinemann V</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Sharma+NK%22">Sharma NK</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Findlay+MP%22">Findlay MP</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ricke+J%22">Ricke J</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Peeters+M%22">Peeters M</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Perez+D%22">Perez D</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Robinson+BA%22">Robinson BA</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Strickland+AH%22">Strickland AH</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ferguson+T%22">Ferguson T</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Rodríguez+J%22">Rodríguez J</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Kröning+H%22">Kröning H</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Wolf+I%22">Wolf I</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Ganju+V%22">Ganju V</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Walpole+E%22">Walpole E</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Boucher+E%22">Boucher E</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Tichler+T%22">Tichler T</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Shacham-Shmueli+E%22">Shacham-Shmueli E</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Powell+A%22">Powell A</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Eliadis+P%22">Eliadis P</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Isaacs+R%22">Isaacs R</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Price+D%22">Price D</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Moeslein+F%22">Moeslein F</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Taieb+J%22">Taieb J</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Bower+G%22">Bower G</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Gebski+V%22">Gebski V</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Van+Buskirk+M%22">Van Buskirk M</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Cade+DN%22">Cade DN</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Thurston+K%22">Thurston K</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France.<br /><searchLink fieldCode="AU" term="%22Gibbs+P%22">Gibbs P</searchLink>; Guy A. van Hazel, University of Western Australia; Tom Ferguson, Royal Perth Hospital; David Price and Geoff Bower, Mount Medical Center, Perth; Alex Powell, Hollywood Private Hospital, Nedlands, Western Australia; Andrew H. Strickland, Monash Medical Centre, Bentleigh, East Victoria; Vinod Ganju, Frankston Private Hospital Peninsula Oncology Centre, Frankston; Peter Gibbs, Western Hospital, Footscray, Victoria; Euan Walpole, Princess Alexandra Hospital, Woolloongabba; Paul Eliadis, Wesley Medical Centre, Milton, Queensland; Val Gebski, NHMRC Clinical Trials Centre, Camperdown; David N. Cade and Kenneth Thurston, Sirtex Medical Limited, North Sydney, New South Wales, Australia; Volker Heinemann, Ludwig-Maximilian-University of Munich, Munich; Jens Ricke, University Clinic Magdeburg; Hendrik Kroening, Schwerpunktpraxis of Haematology and Oncology, Magdeburg, Germany; Navesh K. Sharma, University of Maryland Medical Center; Fred Moeslein, University of Maryland School of Medicine, Baltimore, MD; Mark Van Buskirk, Data Reduction LLC, Chester, NJ; Michael P.N. Findlay, Cancer Trials New Zealand, Auckland; David Perez, Dunedin Hospital, Dunedin; Bridget A. Robinson, Christchurch Hospital, Christchurch; Richard Isaacs, Palmerston North Hospital, Palmerston, New Zealand; Marc Peeters, Antwerp University Hospital, Antwerp, Belgium; Javier Rodríguez, Clinica Universidad de Navarra, Pamplona, Spain; Ido Wolf and Einat Shacham-Shmueli, Sheba Medical Center, Tel-Hashomer; Thomas Tichler, Shaare-Zedek Medical Center, Jerusalem, Israel; Eveline Boucher, Hopital de Jour, Rennes; and Julien Taieb, Georges Pompidou European Hospital, Paris, France. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2016 May 20; Vol. 34 (15), pp. 1723-31. <i>Date of Electronic Publication: </i>2016 Feb 22. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26903575 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/JCO.2015.66.1181 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1723 Titles: – TitleFull: SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: van Hazel GA – PersonEntity: Name: NameFull: Heinemann V – PersonEntity: Name: NameFull: Sharma NK – PersonEntity: Name: NameFull: Findlay MP – PersonEntity: Name: NameFull: Ricke J – PersonEntity: Name: NameFull: Peeters M – PersonEntity: Name: NameFull: Perez D – PersonEntity: Name: NameFull: Robinson BA – PersonEntity: Name: NameFull: Strickland AH – PersonEntity: Name: NameFull: Ferguson T – PersonEntity: Name: NameFull: Rodríguez J – PersonEntity: Name: NameFull: Kröning H – PersonEntity: Name: NameFull: Wolf I – PersonEntity: Name: NameFull: Ganju V – PersonEntity: Name: NameFull: Walpole E – PersonEntity: Name: NameFull: Boucher E – PersonEntity: Name: NameFull: Tichler T – PersonEntity: Name: NameFull: Shacham-Shmueli E – PersonEntity: Name: NameFull: Powell A – PersonEntity: Name: NameFull: Eliadis P – PersonEntity: Name: NameFull: Isaacs R – PersonEntity: Name: NameFull: Price D – PersonEntity: Name: NameFull: Moeslein F – PersonEntity: Name: NameFull: Taieb J – PersonEntity: Name: NameFull: Bower G – PersonEntity: Name: NameFull: Gebski V – PersonEntity: Name: NameFull: Van Buskirk M – PersonEntity: Name: NameFull: Cade DN – PersonEntity: Name: NameFull: Thurston K – PersonEntity: Name: NameFull: Gibbs P IsPartOfRelationships: – BibEntity: Dates: – D: 20 M: 05 Text: 2016 May 20 Type: published Y: 2016 Identifiers: – Type: issn-electronic Value: 1527-7755 Numbering: – Type: volume Value: 34 – Type: issue Value: 15 Titles: – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Type: main |
| ResultId | 1 |
